Atelosteogenesis Type II: Pathophysiology, Genetics, and Skeletal Phenotypes

Overview

Atelosteogenesis Type II (AO2) is a rare, perinatal-lethal skeletal dysplasia characterized by severe short-limb dwarfism with a normal-sized skull, cleft palate, distinctive facial dysmorphism, and the classic “hitchhiker” thumbs (abducted, medially deviated great thumbs) (www.orpha.net). It is caused by biallelic mutations in the diastrophic dysplasia sulfate transporter gene (DTDST), now known as SLC26A2, which disrupt normal cartilage and bone development (www.orpha.net). The disorder is exceedingly rare (prevalence <1 in 1,000,000) (www.orpha.net), with only a handful of cases reported in the medical literature (www.ncbi.nlm.nih.gov). Autosomal recessive inheritance is observed – heterozygous carrier parents (usually asymptomatic) have a 25% chance of an affected child in each pregnancy (pubmed.ncbi.nlm.nih.gov). AO2 is usually perinatally lethal due to respiratory failure from a severely narrow thoracic cage and pulmonary hypoplasia (pubmed.ncbi.nlm.nih.gov). Notably, AO2 lies on a phenotypic continuum with other SLC26A2-related chondrodysplasias: it is intermediate in severity between the milder diastrophic dysplasia (non-lethal) and the more severe achondrogenesis type 1B (most extreme, perinatal lethal) (pubmed.ncbi.nlm.nih.gov). A few long-term survivors of AO2 have been documented, underscoring this spectrum of disease (pubmed.ncbi.nlm.nih.gov).

Molecular Pathophysiology

SLC26A2 encodes a sulfate transporter protein that is predominantly expressed in developing cartilage, responsible for importing sulfate ions into chondrocytes (www.ncbi.nlm.nih.gov). These sulfate ions are required for the sulfation of proteoglycans – key molecules in the cartilage extracellular matrix that give cartilage its structural integrity (www.ncbi.nlm.nih.gov). Loss-of-function mutations in SLC26A2 impair sulfate transport, leading to intracellular sulfate depletion and the synthesis of proteoglycans that are undersulfated (or not sulfated at all) (www.ncbi.nlm.nih.gov). The resultant defective cartilage matrix appears coarse and abnormally sparse in sulfated components, with disorganized fibrillar material and poor cell column formation in growth plates (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). This disrupted cartilage architecture cannot support normal endochondral ossification, causing the severe chondrodysplasia seen in AO2 (marked shortening of bones and delayed/incomplete ossification of skeletal elements) (www.ncbi.nlm.nih.gov). On a biochemical spectrum, residual transporter activity correlates inversely with disease severity – milder SLC26A2 mutations that retain partial function cause milder phenotypes (e.g. multiple epiphyseal dysplasia or diastrophic dysplasia), whereas combinations of severe/null mutations result in the lethal AO2 or achondrogenesis IB phenotypes (www.ncbi.nlm.nih.gov). For example, a recurrent missense mutation p.Arg279Trp (R279W) in SLC26A2 is commonly associated with the atelosteogenesis type II phenotype, especially when present alongside a second, null variant (www.ncbi.nlm.nih.gov). In the Finnish population, a founder splice-site mutation (c.-26+2T>C in SLC26A2) is frequently observed in severe SLC26A2-related dysplasias (including AO2) (medlineplus.gov). Overall, the pathophysiology of AO2 is a failure of proper cartilage extracellular matrix sulfation, leading to structurally weak cartilage in the trachea, ribs, and long bones, which in turn causes skeletal malformations and fatal respiratory compromise (www.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

Hallmark Skeletal Phenotypes

Clinically, AO2 presents with striking skeletal abnormalities evident at birth. There is proportionately short stature with severe rhizomelic limb shortening (marked shortening of the upper arms and thighs) while the skull is relatively normal-sized (pubmed.ncbi.nlm.nih.gov). The hands show the characteristic “hitchhiker thumb,” in which the thumbs are abducted and flexed (often accompanied by ulnar deviation of the other fingers) (pubmed.ncbi.nlm.nih.gov). The feet often have a wide gap between the first and second toes (sandal gap) and clubfoot (talipes equinovarus) deformities (pubmed.ncbi.nlm.nih.gov). Craniofacial and axial features include a cleft palate, a depressed nasal bridge with midface retrusion, hypertelorism or epicanthal folds, and micrognathia (small jaw) (pubmed.ncbi.nlm.nih.gov). The chest is very narrow (thoracic hypoplasia) with short, horizontal ribs, leading to a small lung volume, and the abdomen is protuberant (pubmed.ncbi.nlm.nih.gov). Radiographically, there is generalized platyspondyly (flattened vertebral bodies) and deficient ossification of many bones – for instance, iliac bones can be hypoplastic, long bones are short with flared or irregular metaphyses, and the distal humerus may appear bifid or ribbon-like (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). These skeletal hallmarks, especially the combination of hitchhiker thumbs, clubfeet, and extreme limb shortening with a normal-calvarium, are diagnostic for AO2 (pmc.ncbi.nlm.nih.gov). The profound thoracic restriction caused by the skeletal anomalies typically results in pulmonary hypoplasia and tracheobronchomalacia, explaining the high neonatal mortality (pubmed.ncbi.nlm.nih.gov).

Diagnosis and Outlook

Diagnosis of atelosteogenesis II can be suspected prenatally via ultrasound if severe skeletal shortening and clubfeet are observed, and it is confirmed by identifying biallelic SLC26A2 mutations through molecular genetic testing (www.ncbi.nlm.nih.gov). Given the rarity of the condition, genetic testing panels for lethal skeletal dysplasias or targeted SLC26A2 sequencing are employed when AO2 is suspected (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Carrier screening for at-risk families and prenatal or preimplantation genetic testing can be offered if the familial SLC26A2 mutations are known (pubmed.ncbi.nlm.nih.gov). There is no curative treatment for AO2 – management is limited to supportive care, as most infants succumb shortly after birth due to respiratory failure (myriad.com). In the rare event of an affected infant surviving the neonatal period, aggressive respiratory support and orthopedic interventions (similar to those used in diastrophic dysplasia management) may be attempted, but the prognosis remains poor. Ongoing research in skeletal dysplasias is improving understanding of cartilage sulfation disorders, though atelosteogenesis II’s extreme severity currently precludes any definitive therapy (myriad.com). The emphasis remains on early diagnosis (including prenatal identification) and genetic counseling for families affected by this ultra-rare but devastating skeletal disorder (pubmed.ncbi.nlm.nih.gov) (www.orpha.net).